CA3142494C - Compositions a liberation prolongee d'alpha-cetoglutarate - Google Patents

Compositions a liberation prolongee d'alpha-cetoglutarate

Info

Publication number
CA3142494C
CA3142494C CA3142494A CA3142494A CA3142494C CA 3142494 C CA3142494 C CA 3142494C CA 3142494 A CA3142494 A CA 3142494A CA 3142494 A CA3142494 A CA 3142494A CA 3142494 C CA3142494 C CA 3142494C
Authority
CA
Canada
Prior art keywords
composition
ketoglutarate
calcium
release
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3142494A
Other languages
English (en)
Other versions
CA3142494A1 (fr
Inventor
David Eugene Pereira
Sumana KONAR
Original Assignee
Ponce De Leon Health Designated Activity Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Co filed Critical Ponce De Leon Health Designated Activity Co
Priority claimed from PCT/US2020/036987 external-priority patent/WO2020252014A1/fr
Publication of CA3142494A1 publication Critical patent/CA3142494A1/fr
Application granted granted Critical
Publication of CA3142494C publication Critical patent/CA3142494C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Il est décrit des formulations à libération régulée de calcium alpha-cétoglutarate (Ca-AKG). Les formulations comprennent de l'hydroxypropyleméthyl cellulose (HPMC) et fournissent une libération continue et consistante de Ca-AKG. De telles formulations englobent une composition comprenant (a) Ca-AKG et (b) une matrice de libération contrôlée comprenant de l'hydroxypropyleméthyl cellulose (HPMC) avec un poids moléculaire moyen en nombre d'environ 68 000 à environ 95 000, ou avec un poids moléculaire moyen en nombre d'environ 115 000 à environ 150 000, ou une combinaison de ceux-ci.
CA3142494A 2019-06-10 2020-06-10 Compositions a liberation prolongee d'alpha-cetoglutarate Active CA3142494C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (fr) 2019-06-10 2020-06-10 Compositions à libération prolongée d'alpha-cétoglutarate

Publications (2)

Publication Number Publication Date
CA3142494A1 CA3142494A1 (fr) 2020-12-17
CA3142494C true CA3142494C (fr) 2026-04-14

Family

ID=

Similar Documents

Publication Publication Date Title
US10688058B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US20210290582A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
JP2025124683A (ja) アルファ－ケトグルタル酸塩の持続放出組成物
US20110223249A1 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
JP2017149725A (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
US12178918B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2919213A1 (fr) Composition derivee d'acide folique a liberation modifiee stabilisee, son utilisation therapeutique, et procedes de fabrication
EP1849830B1 (fr) Composition finement divisee contenant un substance peu hydrosoluble
CA3142494C (fr) Compositions a liberation prolongee d'alpha-cetoglutarate
EP2138166A1 (fr) Procédé de production de comprimés
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
HK40071632A (zh) α-酮戊二酸类化合物的持续释放组合物
HK40071632B (zh) α-酮戊二酸类化合物的持续释放组合物
EP2543363A1 (fr) Formes pharmaceutiques solides orales à libération prolongée de dronédarone ou l'un de ses sels pharmaceutiquement acceptables
CN101015535A (zh) 哌克昔林的缓释制剂